EKC-Cide Study Results Presented at National Ophthalmology Meeting
WEST HAVEN, Conn.--(BUSINESS WIRE)--Nov 10, 2008 - NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that the Feinstein Institute of Medical Research scientists presented their study of the "Effect of Topical Nanoviricides in a Rabbit Model of EKC" (epidemic kerato-conjunctivitis) at the 42nd annual meeting of the Ocular Microbiology and Immunology Group (OMIG) in Atlanta, Georgia, on Friday, November 7, 2008. The OMIG meeting was held in conjunction with the International Joint Meeting of the American Academy of Ophthalmology (AAO) and the European Society of Ophthalmology (SEO).
"The presentation was received with great enthusiasm," said Dr. Howard Fields, Vice-President of Virology, NanoViricides, Inc., adding, "In fact, the prestigious Thygeson Lecturer this year, Dr. Y. J. Gordon, made several references to EKC-Cide(TM) as a highly promising drug for EKC treatment in his survey of the landscape of adenoviral diseases of the eye and their treatment."
Briefly, two broad-spectrum nanoviricides were found to be clinically highly effective against adenoviral EKC. Both significantly reduced conjunctivial injection (severe redness of the eye) as well as blepharitis (stickiness, swelling, furriness). One of the nanoviricides was more effective in rapidly resolving the pathology, than the other one. NanoViricides, Inc. has previously announced the study preliminary findings as they were received by the Company.
The Company believes that such strong clinical findings have not been reported previously for any other safe therapeutics in development against EKC.
"We now have very strong interest from major pharmaceutical companies for the EKC-Cide drug candidate," said Anil R. Diwan, PhD, President of the Company, adding "We are working towards Materials Transfer Agreements so that our potential Pharma partners may conduct further evaluations of EKC-Cide on their own."
At present there are no drugs available for the treatment of viral EKC.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, and dengue fever, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
Contact
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
